Amanote Research
Register
Sign In
Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Clinical Cancer Research
- United States
doi 10.1158/1078-0432.ccr-15-0185
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
April 30, 2015
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)